-
Epoxomicin: Mechanism and Research Workflow
2026-09-02
Epoxomicin is a selective, irreversible proteasome inhibitor used to interrogate protein degradation and ubiquitin-proteasome pathway research. Its α',β'-epoxyketone group supports covalent proteasome engagement, while the A2606 product information reports a 4 nM IC50 for chymotrypsin-like activity.
-
Epoxomicin for ER Stress and Proteasome Flux
2026-09-02
Epoxomicin is a selective, irreversible proteasome inhibitor for connecting protein degradation measurements with ER-stress biology. This guide explains how to use it to distinguish proteasome-dependent clearance from upstream ubiquitination and stress-sensor regulation.
-
GMDS and Core Fucosylation in MYCN Neuroblastoma
2026-09-01
This 2025 Oncogene study combines spatial glycomics, transcriptional assays, and functional perturbation to identify GMDS-driven de novo GDP-fucose synthesis as a metabolic determinant of core fucosylation in MYCN-amplified neuroblastoma. The findings connect a genetic risk feature with tumor-associated glycan remodeling and suggest a rationale for testing GDP-fucose metabolism as a therapeutic vulnerability.
-
PEGylated Iron Oxide Nanoparticles in the Liver
2026-09-01
This ACS Nano study clarifies how iron oxide nanoparticle size and PEG chain length jointly shape hepatic accumulation and uptake by distinct liver cell populations. Its central contribution is the integration of radiotraced in vivo biodistribution with primary-cell experiments, revealing that hepatocytes and stellate cells can be important nanoparticle sinks rather than Kupffer cells being the sole dominant mediators of clearance.
-
Cy5 maleimide (non-sulfonated): Labeling Guide
2026-08-31
Cy5 maleimide (non-sulfonated) provides a thiol-reactive route for covalently labeling accessible cysteine residues in peptides and proteins for imaging and assay readouts. Because the reagent has low aqueous solubility, it should be prepared in DMSO or ethanol and should not be added directly to an aqueous biomolecule sample without co-solvent validation.
-
Calcitriol B2141 for Reliable Cell Assays
2026-08-31
Learn how Calcitriol (SKU B2141), the active 1,25-dihydroxy vitamin D3 metabolite, can support better-controlled proliferation, viability, cytotoxicity, VDR, immune, and cancer signaling experiments. This scenario-based guide covers solvent preparation, assay interpretation, orthogonal controls, and practical vendor-selection criteria.
-
WY-14643 in PPARα Metabolic Research
2026-08-30
WY-14643 (Pirinixic Acid) provides a practical way to activate PPARα while tracking lipid metabolism, inflammatory signaling, and insulin sensitivity in cell and animal models. This guide connects disciplined compound handling with a multiomics-inspired workflow for studying endothelial inflammation and PPARα-linked tumor biology.
-
Apigenin: An Assay-First Translational Framework
2026-08-29
Apigenin research spans malignant mesothelioma, epigenetic regulation, oxidative stress, and Alzheimer’s disease models. This assay-first guide connects the evidence to practical decisions about controls, formulation, readouts, and translational interpretation.
-
Carfilzomib: From Proteasome Blockade to Translation
2026-08-28
Carfilzomib (PR-171) offers translational researchers a mechanistically precise way to interrogate irreversible proteasome inhibition, proteotoxic stress, apoptosis, and rational combination strategies in cancer models.
-
T7 RNA Polymerase for RNA Research Workflows
2026-08-28
Build reproducible RNA workflows for probes, functional transcripts, RNAi experiments, and RNA vaccine production with promoter-specific transcription. This guide connects practical template design and reaction optimization with assay choices inspired by a colorectal cancer study of DDX21, SIRT7, NAT10, and ac4C RNA modification.
-
Toremifene Workflows for Prostate Cancer Research
2026-08-27
Toremifene provides a concentration-controlled way to interrogate estrogen receptor biology alongside metastatic signaling in prostate cancer models. This practical guide connects an in vitro cell growth inhibition assay with calcium, migration, protein-stability, and combination workflows while emphasizing controls, storage, and interpretation limits.
-
SB203580: Mechanism, Benchmarks, and Workflow
2026-08-27
SB203580 is an ATP-competitive, selective p38 MAPK inhibitor used to dissect stress and inflammatory signaling. Its reported p38 MAPK potency is 0.3–0.5 μM, but the compound does not by itself establish a p38 mechanism in the cited nanoplastic vascular study, which examined ERK signaling.
-
Moxidectin’s Antifungal Potential Beyond Deworming
2026-08-26
Moxidectin is moving from an established macrocyclic lactone anthelmintic into an emerging antifungal combination strategy. New evidence shows that it elevates Candida albicans ergosterol and potentiates polyenes, creating a translational opportunity that still requires rigorous mechanistic, formulation, safety, and resistance studies.
-
Affordable GRO-seq in Bread Wheat: Study Insights
2026-08-26
This STAR Protocols study presents a cost-conscious GRO-seq workflow for profiling nascent transcription in allohexaploid bread wheat. Its central innovation is rRNA depletion after nuclear RNA isolation and before nascent RNA immunoprecipitation, which increased the proportion of valid data by 20-fold and improved enhancer-transcription analysis in a complex plant genome.
-
Epoxomicin: A Causal Probe of RIPK3 Degradation
2026-08-25
Epoxomicin is a selective, irreversible proteasome inhibitor that can turn proteasome-dependent RIPK3 loss into a testable mechanistic hypothesis. This article translates viral inflammation findings into practical assay design, controls, interpretation rules, and reproducible handling guidance.